July 23rd 2025
The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension
Azarga receives positive CHMP opinion
October 13th 2008Azarga (brinzolamide 1%/timolol 0.5% ophthalmic suspension; Alcon Laboratories) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which recommends Azarga be granted marketing authorization from the European Medicines Agency (EMEA).